JLJer-Yuh Liu

Jer-Yuh Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jer-Yuh Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Jin-Ming Hwang

    Department of Applied Chemistry, School of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

    2 shared publications
  • Chang-Hai Tsai

    Department of Healthcare Administration, Asia University, Taichung, Taiwan

    1 shared publication
  • Chau-Jong Wang

    Institute of Biochemistry and Biotechnology, Chung Shan Medical University, 110, Section 1, Chien-Kuo North Road, Taichung 402, Taiwan

    1 shared publication
  • Cheng-Chung Wu

    Department of General Surgery, Taichung Veterans General Hospital, Taichung, Taiwan

    1 shared publication
  • Chih-Yang Huang

    Department of Precision Chinese Herbal Medicine and Molecular Medicine Research, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan

    1 shared publication
  • Chung-Jung Liu

    Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

    1 shared publication

Latest Publications

  • Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells

    by Jin-Ming Hwang, Shao-Hsuan Kao, Yi-Hsien Hsieh, Kuen-Lin Li, Pei-Hsi Wang, Li-Song Hsu, Jer-Yuh Liu

    Anion exchanger (AE) 2, belonging to the chloride–bicarbonate transporter family, has been reported to involve cell survival for hepatocellular carcinoma (HCC) cells. Our previous findings showed that AE2 gene was highly expressed in a poorly differentiated HCC cell line, HA22T/VGH. Additionally, treatment with 4,4′-diisothiocyanatostilbene-2,20-disulfonic acid (DIDS), an AE-specific inhibitor, significantly inhibited cell proliferation and induced cell apoptosis for the HA22T/VGH. To further investigate the biological functions of AE2 in human HCC, suppression of AE2 expression by the antisense oligonucleotide-AE2 (AS-AE2) was performed, and the cell viability, cell cycle regulation, and cell apoptosis for HCC cell lines were monitored. The results showed that AS-AE2 treatment could efficiently suppress the mRNA expression of AE2 for various differentiated HCC cells, including HA22T/VGH, SK-Hep-1, PLC/PRF/5, Hep3B, and HepG2. Moreover, AS-AE2 treatment significantly reduced cell viability, arrested cell cycle at sub-G1 phase, and induced cell apoptosis for the poorly differentiated HA22T/VGH, but not for other moderately or well-differentiated HCC cell lines. The findings indicated that AE2 may play an important role in the progression of HCC cells, and provide a new strategy for the development of therapeutic treatment against human HCC.


  • Apoptosis in meningoencephalitis of Angiostrongylus cantonensis-infected mice

    by Ke-Min Chen, Hsiu-Hsiung Lee, Shih-Chan Lai, Li-Sung Hsu, Chau-Jong Wang, Jer-Yuh Liu


  • Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis

    by Chung-Jung Liu, Jin-Ming Hwang, Trang-Tiau Wu, Yi-Hsien Hsieh, Cheng-Chung Wu, Yih-Shou Hsieh, Chang-Hai Tsai, Hsi-Chin Wu, Chih-Yang Huang, Jer-Yuh Liu

    Anion exchangers (AEs) of the Cl-/HCO3- exchanger family contribute to the regulation of intracellular acid-base balance. Recently, we found that anion exchanger 2 (AE2) was significantly expressed in human hepatocellular carcinoma (HCC) and in poorly-differentiated human HCC HA22T/VGH cells. In the present study, we further explored the pharmacological function of AE in four human HCC cell lines (SK-Hep-1, HA22T/VGH, HepG2, and Hep3B) following the treatment of 4,4’-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS), an AEs specific inhibitor. After administrations with 400–1000 μM of DIDS, cell proliferation was greatly inhibited in a dose-dependent manner from 47.5 to 65.0% in higher malignant HA22T/VGH cells, but not in other cell lines. The results of 4,6-diamidino-2-phenylindole (DAPI) staining, DNA fragmentation and flow cytometric analysis further revealed that cell apoptosis induced by DIDS was also observed in HA22T/VGH cells. Therefore, these findings suggested that AE may be involved, in part, in the proliferation and survival of HA22T cells and could be a new potential therapeutic target against specific human HCC.


  • Reduction of PKCα decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma

    by Trang‐Tiau Wu, Yi‐Hsien Hsieh, Yih‐Shou Hsieh, Jer‐Yuh Liu

    Protein kinase C (PKC) superfamily play key regulatory roles on the development of cancer. However, the exact role of these enzymes in human hepatocellular carcinoma (HCC) has not been well established. Using the RT‐PCR and Western blotting to analyze the levels of PKC isoforms mRNA and protein in the five different differentiated hepatoma cell lines, we found that PKCα was highly expressed in the poor‐differentiated HCC cell lines (SK‐Hep‐1 and HA22T/VGH) as compared with that in the well‐differentiated HCC cell lines (PLC/PRF/5, Hep3B, and HepG2). When treated with PKCα antisense oligonucleotides (ODN), both HA22T/VGH and SK‐Hep‐1 cells lines showed the reduction of PKCα expression, as well as a deceleration in the growth rate and in the level of cyclin D1, but the increase in the levels of p53 and p21WAF1/CIP1. Moreover, the reduction of PKCα expression also inhibited the migratory and invasive potential of both HA22T/VGH and SK‐Hep‐1 cells lines, and revealed a down‐regulation of several migration/invasion‐related genes (MMP‐1, u‐PA, u‐PAR, and FAK). These phenomenon were also confirmed by DNA‐based small interfering RNA (siRNA) PKCα and PKCα/β specific inhibitor Go6976. Thus, the results indicated that PKCα may be associated with regulation of cell proliferation/migration/invasion in human poorly differentiated HCC cells, suggesting a role for the PKCα in the malignant progression of human HCC. J. Cell. Biochem. 103: 9–20, 2008.